Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4473 |
Name | sarcomatoid renal cell carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma sarcomatoid renal cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03024996 | Phase III | Atezolizumab | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) | Terminated | USA | TUR | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT03685448 | Phase II | Cabozantinib | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB) | Unknown status | AUS | 0 |
NCT03866382 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors | Recruiting | USA | 1 |
NCT04267120 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) | Active, not recruiting | USA | 0 |
NCT04413123 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Recruiting | USA | 0 |
NCT04627064 | Phase I | Abemaciclib + Belzutifan Abemaciclib | ABEMA Alone or in COMBO With MK-6482 | Active, not recruiting | USA | 0 |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |